- Home
- ONFO vs VRAX Comparison
ONFO vs VRAX Comparison
Compare ONFO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- VRAX
- Stock Information
- Founded
- ONFO 2018
- VRAX 2013
- Country
- ONFO United States
- VRAX United Kingdom
- Employees
- ONFO N/A
- VRAX N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ONFO Technology
- VRAX Health Care
- Exchange
- ONFO Nasdaq
- VRAX Nasdaq
- Market Cap
- ONFO 5.4M
- VRAX 4.4M
- IPO Year
- ONFO 2022
- VRAX 2022
- Fundamental
- Price
- ONFO $1.31
- VRAX $0.99
- Analyst Decision
- ONFO
- VRAX Strong Buy
- Analyst Count
- ONFO 0
- VRAX 1
- Target Price
- ONFO N/A
- VRAX $3.00
- AVG Volume (30 Days)
- ONFO 83.7K
- VRAX 149.4K
- Earning Date
- ONFO 08-13-2025
- VRAX 02-05-2025
- Dividend Yield
- ONFO N/A
- VRAX N/A
- EPS Growth
- ONFO N/A
- VRAX N/A
- EPS
- ONFO N/A
- VRAX N/A
- Revenue
- ONFO $9,087,118.00
- VRAX $6,331.00
- Revenue This Year
- ONFO N/A
- VRAX $217,274.83
- Revenue Next Year
- ONFO N/A
- VRAX N/A
- P/E Ratio
- ONFO N/A
- VRAX N/A
- Revenue Growth
- ONFO 65.97
- VRAX N/A
- 52 Week Low
- ONFO $0.61
- VRAX $0.74
- 52 Week High
- ONFO $1.88
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- ONFO 61.62
- VRAX 55.13
- Support Level
- ONFO $1.25
- VRAX $0.86
- Resistance Level
- ONFO $1.42
- VRAX $1.10
- Average True Range (ATR)
- ONFO 0.14
- VRAX 0.10
- MACD
- ONFO 0.02
- VRAX 0.02
- Stochastic Oscillator
- ONFO 64.81
- VRAX 47.90
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).